FindTrial
Sign In

SNK01

BIOLOGICAL6 trials

Sponsors

NKGen Biotech, Inc.

Conditions

Advanced CancerAdvanced Solid TumorAlzheimer DiseaseBladder CancerCarcinoma, Non-Small-Cell LungCervical CancerColorectal CancerColorectal Neoplasms

Phase 1

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
CompletedNCT03941262
NKGen Biotech, Inc.Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer +4
Start: 2019-07-15End: 2023-02-17Updated: 2023-11-13
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
WithdrawnNCT04464967
NKGen Biotech, Inc.Advanced Solid Tumor, Bladder Cancer, Cervical Cancer +14
Start: 2021-03-31End: 2023-02-28Updated: 2021-05-12
Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)
TerminatedNCT04678453
NKGen Biotech, Inc.Alzheimer Disease, Neuro-Degenerative Disease
Start: 2021-01-06End: 2024-01-31Updated: 2024-03-01
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
TerminatedNCT05099549
NKGen Biotech, Inc.Advanced Solid Tumor, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms +3
Start: 2021-11-03End: 2023-09-21Updated: 2024-03-01
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
RecruitingNCT06189963
NKGen Biotech, Inc.Moderate Alzheimer Disease
Start: 2023-11-21End: 2026-06-30Target: 36Updated: 2025-11-10

Phase 2

Open-Label Extension Protocol to SNK01-AD01 Study
RecruitingNCT07228078
NKGen Biotech, Inc.Alzheimer Disease
Start: 2025-06-30End: 2028-04-30Target: 30Updated: 2025-11-13

Related Papers

Mechanism of Action of Troculeucel (Non‐genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) in Alzheimer's Disease Confirmed by Corresponding Phase I Biomarker Data.
Alzheimer s & Dementia2025-12-01
Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study.
2025-02-122 citations
Use of Expanded Non‐genetically Modified Natural Killer Cells (SNK01) with Enhanced Cytotoxicity in Patients with Advanced Alzheimer’s Disease – Interim Report of a Phase I trial
Alzheimer s & Dementia2023-12-01
AFM24 in combination with autologous NK cells (SNK01) in patients with advanced/metastatic epidermal growth factor receptor (EGFR) expressing solid tumors: Initial results from the phase 1 dose-escalation study.
JCO Global Oncology2023-08-013 citations
Interim analysis of a phase I study of SNK01 (Autologous Nongenetically Modified Natural Killer Cells with Enhanced Cytotoxicity) and avelumab in advanced refractory sarcoma.
Journal of Clinical Oncology2022-06-014 citations
The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors.
Journal of Clinical Oncology2022-06-012 citations
Preliminary analysis of a phase I study of SNK01 (Autologous Non-genetically Modified Natural Killer Cells With Enhanced Cytotoxicity) monotherapy in patients with advanced solid tumors.
Journal of Clinical Oncology2022-06-012 citations
Phase I study of SNK01 (autologous non-genetically modified natural killer cells with enhanced cytotoxicity) in refractory metastatic solid tumors.
Journal of Clinical Oncology2020-05-203 citations